Pfizer today revised its forecast for sales of its Covid-19 vaccine for the full year by 7.5% to $ 36 billion, as it signs aid agreements with countries and receives approvals for the use of vaccines in older age groups.
The company also said it was on track to deliver 2.3 billion doses of vaccine, up from about 3 billion it plans to make this year.
In an unprecedented immunization effort against the COVID-19 pandemic worldwide, the Pfizer vaccine quickly became one of the best-selling products in the company's 172-year history. The company shares the costs and benefits of the vaccine equally with its German partner, BioNTech.
Other competitors, such as Moderna and Johnson & Johnson, have encountered production problems, which has helped Pfizer expand its lead in signing supply agreements with various countries.
Pfizer is also releasing booster doses of the vaccine while awaiting the outcome of a meeting of US regulators later today on the use of its vaccine in children aged 5-11.
The vaccine had $ 13 billion in sales in the third quarter, with analysts expecting an average of $ 10.88 billion, according to a Refinitiv survey.
Source: ΑΠΕ-ΜΠΕ
Italy is heading for the extension of the green pass and the state of emergency
